These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29285948)

  • 1. Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.
    Mu Q; Yu J; McConnachie LA; Kraft JC; Gao Y; Gulati GK; Ho RJY
    J Drug Target; 2018; 26(5-6):435-447. PubMed ID: 29285948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smart cancer nanomedicine.
    van der Meel R; Sulheim E; Shi Y; Kiessling F; Mulder WJM; Lammers T
    Nat Nanotechnol; 2019 Nov; 14(11):1007-1017. PubMed ID: 31695150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic applications of peptide-based nanoformulations for growth factor defective cancers.
    Ghosh A; Maske P; Patel V; Dubey J; Aniket K; Srivastava R
    Int J Biol Macromol; 2024 Mar; 260(Pt 2):129151. PubMed ID: 38181914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating 3D printed pharmaceuticals: From hype to real-world clinical applications.
    Seoane-Viaño I; Trenfield SJ; Basit AW; Goyanes A
    Adv Drug Deliv Rev; 2021 Jul; 174():553-575. PubMed ID: 33965461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale.
    Feng J; Markwalter CE; Tian C; Armstrong M; Prud'homme RK
    J Transl Med; 2019 Jun; 17(1):200. PubMed ID: 31200738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
    Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
    Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of pharmacokinetic modeling of nanomedicines.
    Lebreton V; Legeay S; Saulnier P; Lagarce F
    Drug Discov Today; 2021 Oct; 26(10):2259-2268. PubMed ID: 33892140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging nanomedicine applications and manufacturing: progress and challenges.
    Sartain F; Greco F; Hill K; Rannard S; Owen A
    Nanomedicine (Lond); 2016 Mar; 11(6):577-80. PubMed ID: 26911307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in nanomedicine clinical translation.
    Metselaar JM; Lammers T
    Drug Deliv Transl Res; 2020 Jun; 10(3):721-725. PubMed ID: 32166632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
    Pearce AK; O'Reilly RK
    Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical translation of nanomedicines: Challenges, opportunities, and keys.
    Younis MA; Tawfeek HM; Abdellatif AAH; Abdel-Aleem JA; Harashima H
    Adv Drug Deliv Rev; 2022 Feb; 181():114083. PubMed ID: 34929251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Particle Size in Translational Research of Nanomedicines for Successful Drug Delivery: Discrepancies and Inadequacies.
    Chan HW; Chow S; Zhang X; Kwok PCL; Chow SF
    J Pharm Sci; 2023 Sep; 112(9):2371-2384. PubMed ID: 37453526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
    Shi J; Xiao Z; Kamaly N; Farokhzad OC
    Acc Chem Res; 2011 Oct; 44(10):1123-34. PubMed ID: 21692448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
    Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
    Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues affecting nanomedicines on the way from the bench to the market.
    Longo JPF; Mussi S; Azevedo RB; Muehlmann LA
    J Mater Chem B; 2020 Dec; 8(47):10681-10685. PubMed ID: 33155000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.